自体CIK细胞联合化疗治疗转移性肾癌的临床疗效

doi:10.3971/j.issn.1000-8578.2012.06.028

自体CIK细胞联合化疗治疗转移性肾癌的临床疗效

Clinical Efficacy of Autologous CIK Cell Adoptive Immunotherapy Combined with Chemotherapy in Patients Withmetastatic Renal Cell Carcinoma

摘要

摘要: 目的评价化疗联合自体CIK（cytokine-induced killer）细胞治疗转移性肾癌的临床疗效及安全性。方法19例转移性肾癌患者接受至少1周期的5-氟尿嘧啶和(或)吉西他滨（5-fluorouracil/gemcitabine，5-Fu/Gem）化疗，化疗结束后接受4～8次CIK细胞治疗，细胞回输后应用3天d1~d3白细胞介素-2（interleukin-2，IL-2）和胸腺肽α-1。结果 19例患者中1例部分缓解（PR），13例稳定（SD），5例进展（PD），疾病总控制率（CP＋PR＋SD）为73.68%。评价为PD的5例患者无进展生存期（PFS）为(4.43±2.85)月；其余14例患者PFS未到，中位PFS已达11.64月。结论CIK细胞联合化疗治疗转移性肾癌疗效确切，疾病控制率得到明显提高，患者带瘤生存时间明显延长。

Abstract: Objective To evaluate the clinical efficacy and safety of autologous CIK cell adoptive immunotherapy combined with chemotherapy in patients with metastatic renal cell carcinoma (mRCC). Methods Ninteen mRCC patients were enrolled and received at least one cycle of 5-fluorouracil/gemcitabine regimen chemotherapy，followed by 4-8 times of CIK cell transfusion and 3 doses(d1~d3) of interleukin-2 (IL -2) and Thymosin α1. Results Among the 19 cases，PR,SD and PD were 1，13 and 5,respectively.Disease control rate (CR+PR+SD) was 73.68%.PFS in 5 patients with PD was 4.43±2.85 months，while PFS in the other 14 cases has reached 11.64 months. Conclusion Our results indicated that autologous CIK cell adoptive immunotherapy combined with chemotherapy has potential benefits and might provide a potent treatment approach for mRCC patients.

HTML全文

参考文献(17)

施引文献

资源附件(0)